Citi analyst Samantha Semenkow initiated coverage of 9 Meters Biopharma with a Neutral rating and $2.70 price target. The company’s cash runway is only sufficient to support operations through Q1 of 2023 and management is currently exploring all options for financing, the analyst tells investors in a research note. Citi is on the sidelines ahead of assurance that additional capital has been secured. It finds it difficult to recommend a stock "that has such a short runway."
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly